针对胶质母细胞瘤肿瘤和脑转移的 SRC：原理和临床前研究。
Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.
机构信息
Cleveland Clinic Main Campus, Cleveland, OH 44195, USA.
出版信息
Cancer Lett. 2010 Dec 8;298(2):139-49. doi: 10.1016/j.canlet.2010.08.014.
Abstract
Glioblastoma (GBM) is an extremely aggressive, infiltrative tumor with a poor prognosis. The regulatory approval of bevacizumab for recurrent GBM has confirmed that molecularly targeted agents have potential for GBM treatment. Preclinical data showing that SRC and SRC-family kinases (SFKs) mediate intracellular signaling pathways controlling key biologic/oncogenic processes provide a strong rationale for investigating SRC/SFK inhibitors, e.g., dasatinib, in GBM and clinical studies are underway. The activity of these agents against solid tumors suggests that they may also be useful in treating brain metastases. This article reviews the potential for using SRC/SFK inhibitors to treat GBM and brain metastases.
摘要
胶质母细胞瘤（GBM）是一种侵袭性强、预后差的肿瘤。贝伐单抗治疗复发性 GBM 的监管批准证实了分子靶向药物在 GBM 治疗中的潜力。临床前数据表明，SRC 和 SRC 家族激酶（SFKs）介导控制关键生物学/致癌过程的细胞内信号通路，为研究 SRC/SFK 抑制剂（如达沙替尼）在 GBM 中的作用提供了强有力的依据，并且正在进行临床研究。这些药物对实体瘤的活性表明，它们在治疗脑转移瘤方面也可能有用。本文综述了使用 SRC/SFK 抑制剂治疗 GBM 和脑转移瘤的潜力。
相似文献
1
Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.针对胶质母细胞瘤肿瘤和脑转移的 SRC：原理和临床前研究。
Cancer Lett. 2010 Dec 8;298(2):139-49. doi: 10.1016/j.canlet.2010.08.014.
2
Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.改善胶质母细胞瘤患者的预后：靶向Src的理论依据。
J Neurooncol. 2009 Nov;95(2):151-163. doi: 10.1007/s11060-009-9916-2. Epub 2009 May 13.
3
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.在原位裸鼠模型中，靶向SRC家族激酶可抑制前列腺癌的生长和淋巴结转移。
Cancer Res. 2008 May 1;68(9):3323-33. doi: 10.1158/0008-5472.CAN-07-2997.
4
Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion.靶向Src 家族激酶抑制贝伐珠单抗诱导的脑胶质瘤细胞侵袭。
PLoS One. 2013;8(2):e56505. doi: 10.1371/journal.pone.0056505. Epub 2013 Feb 14.
5
Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.Fyn和SRC是胶质母细胞瘤患者致癌表皮生长因子受体信号传导的效应器。
Cancer Res. 2009 Sep 1;69(17):6889-98. doi: 10.1158/0008-5472.CAN-09-0347. Epub 2009 Aug 18.
6
The role of Src in prostate cancer.Src在前列腺癌中的作用。
Ann Oncol. 2007 Nov;18(11):1765-73. doi: 10.1093/annonc/mdm086. Epub 2007 Apr 10.
7
Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma.鉴定咪唑并[4,5-c]吡啶-2-酮衍生物作为新型Src 家族激酶抑制剂对抗神经胶质瘤。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):1541-1552. doi: 10.1080/14756366.2021.1948542.
8
Src family kinases differentially influence glioma growth and motility.Src家族激酶对胶质瘤的生长和运动性有不同影响。
Mol Oncol. 2015 Nov;9(9):1783-98. doi: 10.1016/j.molonc.2015.06.001. Epub 2015 Jun 10.
9
Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.达沙替尼抑制Src家族激酶可阻断人黑色素瘤细胞的迁移和侵袭。
Mol Cancer Res. 2008 Nov;6(11):1766-74. doi: 10.1158/1541-7786.MCR-08-0169.
10
Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.联合抑制 IGF-1R/IR 和 Src 家族激酶通过减少激活的存活途径增强前列腺癌的抗肿瘤作用。
PLoS One. 2012;7(12):e51189. doi: 10.1371/journal.pone.0051189. Epub 2012 Dec 26.
引用本文的文献
1
Selective Modulation of Trk Receptors by -Organopeptides.有机肽对Trk受体的选择性调节
ACS Chem Neurosci. 2025 Aug 6;16(15):2776-2784. doi: 10.1021/acschemneuro.4c00833. Epub 2025 Jul 9.
2
Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.多形性胶质母细胞瘤：对发病机制、关键信号通路及治疗策略的见解
Mol Cancer. 2025 Feb 26;24(1):58. doi: 10.1186/s12943-025-02267-0.
3
Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma.靶向EPHB2/ABL1可恢复室管膜瘤临床前模型中的抗肿瘤免疫力。
Proc Natl Acad Sci U S A. 2025 Jan 28;122(4):e2319474122. doi: 10.1073/pnas.2319474122. Epub 2025 Jan 22.
4
Advancing brain immunotherapy through functional nanomaterials.通过功能性纳米材料推进脑免疫治疗。
Drug Deliv Transl Res. 2025 Jan 9. doi: 10.1007/s13346-024-01778-5.
5
Fyn, an important molecule in the brain, is a potential therapeutic target for brain tumours.Fyn是大脑中的一种重要分子，是脑肿瘤潜在的治疗靶点。
Front Pharmacol. 2024 Dec 4;15:1485919. doi: 10.3389/fphar.2024.1485919. eCollection 2024.
6
Sleep loss-induced oncogenic pathways are mediated via the neuron-specific interleukin-1 receptor accessory protein (AcPb).睡眠缺失诱导的致癌途径是通过神经元特异性白细胞介素-1受体辅助蛋白（AcPb）介导的。
Brain Behav Immun. 2025 Jan;123:411-421. doi: 10.1016/j.bbi.2024.09.029. Epub 2024 Sep 28.
7
Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance.YES1 在癌症中的新兴作用：耐药性的潜在靶点。
Int J Mol Sci. 2024 Jan 25;25(3):1450. doi: 10.3390/ijms25031450.
8
NRF2 connects Src tyrosine kinase to ferroptosis resistance in glioblastoma.NRF2 将Src 酪氨酸激酶与脑胶质母细胞瘤的铁死亡抗性联系起来。
Life Sci Alliance. 2023 Oct 25;7(1). doi: 10.26508/lsa.202302205. Print 2024 Jan.
9
Identification and Biological Characterization of the Pyrazolo[3,4-]pyrimidine Derivative SI388 Active as Src Inhibitor.作为Src抑制剂具有活性的吡唑并[3,4-]嘧啶衍生物SI388的鉴定及生物学特性研究
Pharmaceuticals (Basel). 2023 Jul 4;16(7):958. doi: 10.3390/ph16070958.
10
Advances in the expression and function of Fyn in different human tumors.Fyn 在不同人类肿瘤中的表达和功能的研究进展。
Clin Transl Oncol. 2023 Oct;25(10):2852-2860. doi: 10.1007/s12094-023-03167-9. Epub 2023 Apr 24.
本文引用的文献
1
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627).达沙替尼用于复发胶质母细胞瘤目标选择患者的2期试验（RTOG 0627）。
Neuro Oncol. 2015 Jul;17(7):992-8. doi: 10.1093/neuonc/nov011. Epub 2015 Mar 10.
2
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.贝伐珠单抗治疗胶质母细胞瘤后的肿瘤侵袭：人类和小鼠的影像学和病理学相关性。
Neuro Oncol. 2010 Mar;12(3):233-42. doi: 10.1093/neuonc/nop027. Epub 2010 Jan 6.
3
A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM THE TUMOR CELLS.一种可通过与肿瘤细胞分离的因子传播的家禽肉瘤。
J Exp Med. 1911 Apr 1;13(4):397-411. doi: 10.1084/jem.13.4.397.
4
Synapse formation regulated by protein tyrosine phosphatase receptor T through interaction with cell adhesion molecules and Fyn.蛋白酪氨酸磷酸酶受体T通过与细胞黏附分子和Fyn相互作用来调节突触形成。
EMBO J. 2009 Nov 18;28(22):3564-78. doi: 10.1038/emboj.2009.289. Epub 2009 Oct 8.
5
Protein-tyrosine phosphatase alpha acts as an upstream regulator of Fyn signaling to promote oligodendrocyte differentiation and myelination.蛋白酪氨酸磷酸酶α作为 Fyn 信号的上游调节剂促进少突胶质细胞分化和髓鞘形成。
J Biol Chem. 2009 Nov 27;284(48):33692-702. doi: 10.1074/jbc.M109.061770. Epub 2009 Oct 6.
6
Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.人表皮生长因子受体2阳性乳腺癌与中枢神经系统转移
J Clin Oncol. 2009 Nov 1;27(31):5278-86. doi: 10.1200/JCO.2008.19.8481. Epub 2009 Sep 21.
7
The pathobiology of glioma tumors.神经胶质瘤肿瘤的病理生物学。
Annu Rev Pathol. 2010;5:33-50. doi: 10.1146/annurev-pathol-121808-102109.
8
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.贝伐单抗单药及联合伊立替康治疗复发性胶质母细胞瘤。
J Clin Oncol. 2009 Oct 1;27(28):4733-40. doi: 10.1200/JCO.2008.19.8721. Epub 2009 Aug 31.
9
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.已经携带对伊马替尼耐药的Bcr-Abl激酶结构域突变的费城染色体阳性患者，发生与对二线或三线酪氨酸激酶抑制剂耐药相关的其他突变的可能性更高。
Blood. 2009 Sep 3;114(10):2168-71. doi: 10.1182/blood-2009-01-197186. Epub 2009 Jul 9.
10
Latent bone metastasis in breast cancer tied to Src-dependent survival signals.乳腺癌中的潜伏性骨转移与Src依赖性生存信号相关。
Cancer Cell. 2009 Jul 7;16(1):67-78. doi: 10.1016/j.ccr.2009.05.017.
Zotero 插件